Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update
Agreement with Janssen Established to Co-Promote Balversa Sacituzumab Govitecan Licensed to Everest Medicines for Greater China and Certain Asian Countries Resubmission of Biologics License Application Targeted for Early Fourth Quarter 2019 Phase 3 TROPICS …